Big Picture Thesis: Since Afrezza’s approval MannKind’s (NASDAQ:MNKD) shares have declined more than 50% as enthusiasm for their partnership with Sanofi-Aventis (NYSE:SNY) has …
In a research report released today, Jefferies analyst Shaunak Deepak initiated coverage on shares of MannKind (NASDAQ:MNKD) with a Buy rating and a $10 price target, …
